Zhongmao Bencao Pharmaceutical

Zhongmao Bencao Pharmaceutical is a clinical-stage biotechnology company based in Beijing, China, specializing in the modernization of Traditional Chinese Medicine (TCM) and the development of innovative natural product-derived therapeutics. The company focuses on high-unmet-need areas such as metabolic diseases and chronic liver conditions, specifically non-alcoholic steatohepatitis (NASH). Its lead candidate, ZM-001, is a small molecule derived from botanical sources designed to address liver inflammation and fibrosis through multi-target metabolic regulation. Zhongmao Bencao leverages a proprietary platform for screening and optimizing bioactive compounds to create standardized, evidence-based medicines for global markets.